MARKETS
RELIANCETCSHDFCBANKINFYICICIBANKSBINITCLTBHARTIARTLAXISBANKMARUTISUNPHARMA

Syncom Formulations (India) Ltd.

SYNCOMF · Pharmaceuticals & Drugs
₹22.08
▲ 0.01 (+0.05%)
Market dataas of 22 Oct 2026, 3:59 pm IST
52-week range · NSE19.7% below its high
Low ₹10.21High ₹27.49
116.3% above its low
Today’s range · NSE₹21.13 – ₹23.20
Low ₹21.13High ₹23.20
Opened at ₹22.07; 9.8% between low and high
P/E against its industry5% above the industry median
SYNCOMF27.3
Industry median25.9
Pharmaceuticals & Drugs · median of profitable companies in the industry
Market cap₹2,076 Cr
Current price₹22.08
Volume · NSE2.26 Cr
52w High / Low · NSE₹27 / ₹10
Stock P/E27.3
Industry P/E25.9
Book value₹4.41
Dividend yield0.45%
ROCE26.8%
ROE20.2%
Debt / Equity0.00
EPS (TTM)₹0.81
Face value₹1

Price

Daily candles · NSE

Price history isn’t available for this scrip.

What the numbers say

  • Good return on equity: 3-year ROE 15.1%.
  • Comfortable leverage: debt-to-equity of 0.00.
  • Sales compounded at 29.7% over 3 years.
  • Weak cash conversion (CFO/OP 0.34).
  • Trades above its industry P/E (27.3 vs 25.9).

Generated automatically from reported financials. These are observations, not a recommendation to buy or sell.

  • AGM

Company announcements as filed with the exchanges. Reproduced for information — not a view or a recommendation.

Profit & Loss · ₹ croreFY26FY25FY24FY23FY22
Net Sales489465263224220
Other income3117141512
Total Income521482277239232
Expenditure412411234204200
Operating Profit10972433432
Interest11432
Depreciation75554
Profit before tax10166342726
Tax2516976
Net Profit7649252020
EPS (₹)0.810.530.340.240.26
Net margin %15.610.69.68.99.0

Consolidated figures, as filed with the exchanges. Newest year first.

Balance Sheet · ₹ croreFY26FY25FY24FY23FY22
Equity capital9494949486
Reserves321248194162131
Net worth415342288256217
Total sources422348293260225
Net block9078724347
Capital work in progress000266
Investments12610874142110
Inventory6341212120
Debtors1111081037668
Cash & bank616890
Book value (₹)4.413.643.072.722.52

Consolidated figures, as filed with the exchanges. Newest year first.

Cash Flow · ₹ croreFY26FY25FY24FY23FY22
From operations5823-61116
From investing-51-1883-45-27
From financing-3-68-15358
Net change in cash4-63631-2
Free cash flow7577-34-11
Closing cash516310

Consolidated figures, as filed with the exchanges. Newest year first.

RatiosFY26FY25FY24FY23FY22
ROCE %26.818.811.09.713.7
ROE %20.215.79.38.511.8
PAT margin %15.610.69.68.99.0
EBIT margin %20.914.314.613.412.8
Debt / equity0.000.010.250.320.27
Current ratio3.134.422.551.611.79
Interest cover88.5576.758.598.8114.58
Sales growth %5.276.617.52.118.9
Dividend per share (₹)0.100.000.000.000.03
Payout %12.30.00.00.013.1

Consolidated figures, as filed with the exchanges. Newest year first.

Frequently asked

Syncom Formulations (India) Ltd. (SYNCOMF) last traded at ₹22.08 on the NSE, up +0.05% on the session. Prices on this page are indicative and for information only.

Syncom Formulations (India) Ltd. has traded between ₹10.21 and ₹27.49 over the last 52 weeks on the NSE.

Syncom Formulations (India) Ltd. has a market capitalisation of about ₹2,076 crore.

Syncom Formulations (India) Ltd. trades at a P/E of 27.3, against an industry P/E of 25.9.

Open a trading and Demat account with Labdhi — it is fully digital with paperless KYC — then place a buy order for SYNCOMF from the Labdhi app or web platform.

Yes. You can invest in equities in a staggered manner through Labdhi. Speak to your Labdhi adviser about a plan suited to your goals and risk profile.

Who is actually trading it

Delivery against churn, the deals big enough to be reported, what the insiders did, and the benchmarks that hold Syncom Formulations (India) Ltd..

Loading trading activity…

Exchange filings and end-of-day data, not a live feed. Bulk, block and insider records are published by the exchanges when a threshold is crossed, so they show reportable activity only. For information, not a recommendation to deal, and not a view on any person named above.

Disclosures. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Prices and data on this page are indicative and for information only. Nothing here is investment advice or a recommendation to buy or sell any security. Investors should consider their own objectives, financial situation and risk profile, and may wish to seek independent advice, before investing.

Figures are as reported by the company; consolidated where available. Errors and omissions excepted.

L. F. C. Securities Pvt. Ltd. · Member BSE, NSE, MCX · SEBI Stock Broker INZ000170736 · CDSL IN-DP-281-2016 · AMFI ARN-78991 · Investment Adviser (Non-Individual) INA000011617 · Compliance Officer: Mr. Santosh Patil · santoshp@labdhi.in · 022-35006933 · Investor Grievances: investorgreve@labdhi.in